Tirosint vs Cytomel (Liothyronine): Switching Between Them

What Each Drug Actually Is

Tirosint is levothyroxine sodium packaged in a liquid-filled gel capsule. It supplies T4, the same prohormone your thyroid gland produces in the largest quantity. Cytomel is the brand name for liothyronine sodium, which supplies T3, the biologically active form of thyroid hormone that binds nuclear receptors and drives metabolic activity in every tissue.

The distinction matters because T4 must be converted to T3 by deiodinase enzymes (primarily type 1 and type 2) in peripheral tissues before it exerts most of its effects 1. This conversion step means levothyroxine acts as a reservoir. Serum T4 levels remain relatively stable throughout the day. Liothyronine, by contrast, bypasses conversion entirely. It produces a rapid spike in serum T3 within 2 to 4 hours, followed by a decline that can leave trough levels below the reference range before the next dose. That pharmacokinetic profile is why the American Thyroid Association (ATA) 2014 guidelines consider levothyroxine monotherapy the standard of care for most hypothyroid patients 2.

Tirosint's gel-cap design eliminates many excipients found in standard levothyroxine tablets (lactose, gluten-containing starches, talc, dyes). A 2014 study by Vita et al. in patients with impaired absorption (post-bariatric surgery, atrophic gastritis, or lactose intolerance, among others) found that switching from tablet levothyroxine to the liquid/gel-cap formulation produced significantly better TSH normalization without changing the dose 3. That finding made Tirosint a go-to option for patients whose TSH remains elevated despite adequate dosing of conventional tablets.

Why Patients Consider Switching

The most common reason patients ask about moving from Tirosint to Cytomel (or vice versa) is persistent symptoms. A subset of hypothyroid patients report ongoing fatigue, cognitive fog, weight gain, or depressed mood even when their TSH sits within the reference range on T4 monotherapy.

Bunevicius et al. published a crossover trial in the New England Journal of Medicine (1999, N=33) showing that partial substitution of T3 for T4 improved mood, cognitive function, and physical symptom scores compared with T4 alone 4. That trial generated intense interest in combination therapy. Subsequent larger trials, including the 2003 study by Sawka et al. (N=40) 5 and the 2005 double-blind trial by Escobar-Morreale et al. (N=28) 6, failed to replicate the magnitude of benefit in the general hypothyroid population. The ATA's 2014 systematic review concluded that available evidence does not support routine use of combination T4/T3, but it acknowledged that a subgroup of patients may benefit, and it did not prohibit a trial of combination therapy on a case-by-case basis 2.

Other reasons for switching include cost, side-effect profile, and absorption issues. A patient absorbing Tirosint well but still symptomatic might add low-dose liothyronine. A patient on Cytomel who experiences palpitations or anxiety from T3 peaks might move to T4-only therapy via Tirosint for more stable serum levels.

Dose Conversion When Switching

There is no FDA-approved conversion chart for switching between levothyroxine and liothyronine. The most commonly referenced clinical ratio is 1 mcg of liothyronine to approximately 3 to 4 mcg of levothyroxine, though some endocrinologists use ratios as high as 1:5 based on individual patient response 7.

A patient on Tirosint 100 mcg who is switching to combination therapy might reduce Tirosint to 75 mcg and add Cytomel 5 mcg (using a 1:5 ratio for the replaced portion) or reduce to 88 mcg and add Cytomel 5 mcg (using a 1:3 ratio for 12 mcg of displaced T4). The exact split depends on clinical judgment, patient weight, symptom burden, and baseline free T3 levels. Complete replacement of T4 with T3 monotherapy is rarely done. When it is, a typical starting range is 25 to 50 mcg of liothyronine daily, split into two or three doses, for a patient previously on 100 to 150 mcg of levothyroxine.

Switching in the opposite direction (Cytomel to Tirosint) follows the same ratio in reverse. A patient on Cytomel 25 mcg daily would typically start Tirosint at 75 to 100 mcg, recognizing that the slower onset of T4 means TSH may take 4 to 6 weeks to reach a new steady state, and symptoms from T3 withdrawal (fatigue, cold intolerance) can appear within 48 to 72 hours if the transition is abrupt.

A safer approach for Cytomel-to-Tirosint transitions is to overlap: start the full Tirosint dose while tapering Cytomel by 5 mcg every 1 to 2 weeks. This prevents the symptomatic trough that occurs because T4 needs time to build serum levels and begin peripheral conversion to T3.

Absorption and Bioavailability Differences

Standard levothyroxine tablets have oral bioavailability ranging from 40% to 80%, influenced heavily by food, coffee, calcium, iron, and proton pump inhibitors 8. Tirosint's gel-cap formulation showed reduced sensitivity to these interference factors. Vita et al. demonstrated that patients with documented malabsorption achieved TSH normalization on the same microgram dose when switched from tablets to the gel cap, suggesting higher effective bioavailability 3.

Liothyronine (Cytomel) has approximately 95% oral bioavailability and is less affected by food timing, though the FDA labeling still recommends taking it on an empty stomach 9. The high bioavailability of T3 means that small dose changes (even 5 mcg) produce measurable shifts in serum free T3 and can move TSH substantially.

This asymmetry matters during a switch. Dropping 25 mcg of Tirosint (effective absorbed dose perhaps 10 to 20 mcg of T4) produces a modest change. Adding 5 mcg of Cytomel (effective absorbed dose approximately 4.75 mcg of T3, equivalent to roughly 15 to 20 mcg of T4 in biological activity) produces a proportionally larger hormonal effect. Clinicians experienced with thyroid optimization often make the T3 change first, recheck labs at 4 weeks, and then adjust the T4 dose based on where TSH and free T3 land.

Monitoring After the Switch

The minimum monitoring protocol after any switch between T4 and T3 medications includes TSH plus free T4 and free T3 drawn at 4 to 6 weeks. TSH alone is insufficient when T3 is involved because liothyronine can suppress TSH disproportionately relative to true tissue thyroid status.

Dr. Antonio Bianco, a professor of medicine at the University of Chicago and a leading researcher in thyroid hormone metabolism, has stated: "TSH is a pituitary hormone. It tells you what the pituitary thinks about circulating thyroid hormones, but it does not necessarily reflect what is happening in every tissue" 10. This is particularly relevant for patients on combination therapy or T3 monotherapy, where a suppressed TSH (<0.1 mIU/L) does not always indicate clinical hyperthyroidism if free T3 and free T4 remain within range.

The ATA 2014 guidelines recommend that if combination therapy is used, the goal should be a TSH in the lower half of the reference range (approximately 0.5 to 2.5 mIU/L) with free T3 within the normal range, and that cardiac monitoring (resting heart rate, ECG if indicated) should accompany dose adjustments, especially in patients over 60 or those with cardiovascular disease 2.

Practical monitoring schedule:

• Baseline labs before the switch (TSH, free T4, free T3, total T3)
• Recheck at 4 to 6 weeks
• If dose adjustment is needed, recheck again 4 to 6 weeks later
• Once stable, recheck every 6 to 12 months

Risks and Side Effects to Watch For

Adding T3 (Cytomel) introduces risks that T4-only therapy (Tirosint) largely avoids. The rapid peak-and-trough kinetics of liothyronine can trigger palpitations, tremor, anxiety, insomnia, and heat intolerance, particularly in the first 2 to 4 hours after dosing. These effects are dose-dependent and typically resolve with dose reduction or splitting the daily dose into two or three administrations.

Bone density is a concern with long-term TSH suppression from any cause. A meta-analysis by Uzzan et al. (2009, 25 studies, N=2,987) found that suppressive doses of thyroid hormone were associated with significant bone loss in postmenopausal women but not in premenopausal women or men 11. This finding means that switching to a regimen that includes T3 (which more readily suppresses TSH) requires attention to bone-protective strategies in at-risk populations.

Atrial fibrillation risk also increases with subclinical hyperthyroidism. The Rotterdam Study (N=1,149 euthyroid participants followed for a mean of 8.8 years) demonstrated that even high-normal free T4 levels were associated with increased atrial fibrillation incidence 12. Patients switching to combination therapy should have their resting heart rate and rhythm assessed regularly.

Tirosint-specific risks are minimal beyond those of any levothyroxine product. Gelatin allergy (rare) is a contraindication. The dye-free version (Tirosint-SOL, the oral solution) is available for patients with gelatin sensitivity.

Who Should Not Switch

Not every patient dissatisfied with their current thyroid medication should switch between T4 and T3 formulations. The 2014 ATA guidelines identify several situations where adding or switching to T3 is not recommended 2:

Pregnant patients or those planning pregnancy should remain on levothyroxine monotherapy. Liothyronine crosses the placenta less predictably, and fetal brain development depends on stable maternal T4 levels. Patients with active cardiovascular disease, recent myocardial infarction, or unstable angina should avoid the hemodynamic swings that T3 peaks can produce. Elderly patients (over age 70) are at higher risk for atrial fibrillation and should use T3, if at all, only at low doses with cardiac monitoring.

Patients whose elevated TSH on T4 therapy is driven by poor adherence, incorrect timing relative to meals, or drug interactions (calcium carbonate, ferrous sulfate, proton pump inhibitors) should address those factors first. Switching to Tirosint's gel cap, which is less affected by food and co-medications, may resolve the problem without introducing T3 at all.

Cost and Access Considerations

Tirosint is a brand-name product with no AB-rated generic equivalent in gel-cap form as of 2026. Average retail cost ranges from $80 to $150 for a 30-day supply depending on dose and pharmacy. Tirosint-SOL (the liquid formulation) is similarly priced. Some insurance plans cover Tirosint with prior authorization when the prescriber documents malabsorption or excipient sensitivity.

Generic liothyronine (Cytomel's generic) is inexpensive. A 30-day supply of generic liothyronine 5 mcg or 25 mcg tablets typically costs $10 to $30 at most retail pharmacies. Brand-name Cytomel is more expensive ($50 to $100+). The cost differential means that some patients use generic levothyroxine (not Tirosint) plus generic liothyronine as the most affordable combination approach.

The Endocrine Society's 2012 position statement noted that cost and availability of sustained-release T3 formulations remain barriers to conducting definitive combination therapy trials 13. A sustained-release liothyronine product, which would smooth the peak-trough problem, is not yet commercially available in the United States, though compounding pharmacies prepare slow-release T3 capsules off-label.

The Case for Combination Therapy Instead of a Full Switch

Rather than switching entirely from Tirosint to Cytomel or vice versa, many endocrinologists prefer a partial substitution approach. The European Thyroid Association (ETA) issued a 2012 position statement supporting a trial of combination T4/T3 in patients with persistent symptoms on T4 monotherapy, provided the T3 component is kept at a low dose (ratio of T4:T3 in the range of 13:1 to 20:1 by weight) 13.

Dr. Jacqueline Jonklaas, a professor of endocrinology at Georgetown University Medical Center and co-author of the ATA hypothyroidism guidelines, has noted: "The goal of combination therapy is to approximate the T4-to-T3 ratio that the normal thyroid gland produces, which is roughly 14:1" 2. A practical implementation for a 70 kg patient might be Tirosint 88 mcg plus liothyronine 5 mcg daily, yielding a ratio of approximately 17.6:1.

This approach preserves the absorption advantages of Tirosint while adding a small T3 supplement to address residual symptoms. If the patient responds favorably (improved energy, cognition, mood) and labs remain within target, the combination can be continued long-term. If no benefit is seen after 3 months on an adequate dose, the T3 should be discontinued and other causes of symptoms investigated.

Switching Protocols: Step-by-Step

Tirosint to Cytomel (full switch, uncommon):

1. Determine the current effective T4 dose (e.g., Tirosint 100 mcg).
2. Calculate T3 equivalent using a 1:3 to 1:4 ratio: 100 mcg T4 = approximately 25 to 33 mcg T3.
3. Start Cytomel at 50% to 75% of the calculated T3 dose, split into 2 to 3 daily doses.
4. Taper Tirosint over 1 to 2 weeks while initiating Cytomel.
5. Recheck TSH, free T4, free T3 at 4 to 6 weeks.
6. Adjust Cytomel dose in 5 mcg increments based on labs and symptoms.

Cytomel to Tirosint (full switch):

1. Determine the current T3 dose (e.g., Cytomel 25 mcg daily).
2. Calculate T4 equivalent: 25 mcg T3 = approximately 75 to 100 mcg T4.
3. Start Tirosint at the full calculated dose immediately.
4. Taper Cytomel by 5 mcg every 7 to 14 days.
5. Expect 2 to 3 weeks of overlap before steady-state T4 levels are reached.
6. Recheck labs at 6 weeks after completing the transition.

Tirosint to combination Tirosint + Cytomel (most common):

1. Reduce Tirosint by 12.5 to 25 mcg.
2. Add Cytomel 5 mcg once daily (morning).
3. Recheck labs at 4 to 6 weeks.
4. If TSH remains above target and symptoms persist, increase Cytomel to 5 mcg twice daily before raising Tirosint.